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Hepatitis A in Travelers: The European Experience
Robert Steffen Division of Epidemiology and Prevention of Communicable Diseases.
Institute for Social and Preventive Medicine.
Zurich University. Zurich. Switzerland
Each year "-'14 million Europeans travel to developing countries in Africa, Asia, and Latin
American as well as to infrequently visited countries in eastern Europe. Without protection,
travelers develop symptomatic hepatitis A at the rate of 3 cases per 1000 people per month
of stay. Those who eat and drink under poor hygienic conditions have an even higher risk,
20/1000/month. Studies show that hepatitis A is the most frequent vaccine-preventable disease
in travelers to developing countries. Immunity to hepatitis A virus is infrequent among northern
European travelers, except for those born before 1945, with a history ofjaundice, or who lived for
> 1 year in a developing country.
Only a few decades ago, "turning yellow. . . was taken as
part of the adventure" by expatriates, as recollected by Gen-
eral Norman Schwarzkopf [I]. Travelers today, however. in-
creasingly demand full health during and after a trip, and
therefore, an evaluation of the risk ofhepatitis A in this popu-
lation is essential. Ideally, this should be based on the follow-
ing data: the incidence rate of symptomatic infection in un-
protected travelers, the proportion of anti-hepatitis A virus
(HAV) antibody-negative travelers, and the impact of the
infection, particularly the case-fatality rate.
Unfortunately, there is a paucity of up-to-date concise
data on the subject, and only a few studies have correlated
the number of cases with the number of travelers to various
regions of the world. Further compounding the problem is
that important details, such as the duration of stay abroad
and the immune status of travelers, were not documented or
only incompletely documented. Studies report attack rates
per stay abroad rather than incidence rates per time period.
Nevertheless, it is possible to estimate that the average dura-
tion of stay abroad is ---I month. Although data are limited
and often out-of-date, I provide here some basic estimates of
the risk of hepatitis in European travelers.
Population at Risk
Each year --- 14 million Europeans visit developing coun-
tries where hepatitis A is highly endemic, predominantly
Africa (4 million), Asia (7 million), and Central and South
America (2 million). About 80% of these travelers are tour-
ists, with the remainder consisting of business persons, stu-
dents, foreign aid volunteers, and other professionals and
their families. Another risk group, but one of lower magni-
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tude, is the 70 million northern Europeans who visit and
spend time in southern Europe.
Older seroprevalence surveys indicated that a major pro-
portion of adult travelers were protected by anti-HAV anti-
bodies, and much of the approach to this problem was based
on those findings. However, the demographic data were
based on the immune status of blood donors [2]. Since the
majority of donors generally belong to lower socioeconomic
classes than the traveling population, a higher proportion of
anti-HAV-positive persons is to be expected. Data from re-
cent studies [3-5] that concentrated on travelers and ex-
cluded persons with a history of jaundice or who stayed in
developing countries for prolonged times suggest that the
prevalence rate of anti-HAV antibody among persons born
after 1945 in Germany and Switzerland is very low, defi-
nitely below 20% (figure I).
Risk during International Travel
Since the arrival of techniques to differentiate hepatitis A
from other types of hepatitis, a single retrospective study has
analyzed in detail the risk of travelers importing symptom-
atic hepatitis. Investigators in this Swiss study [6] asked all
laboratories in the Zurich area able to identify anti-HAV IgM
to report all positive cases from 1977 to 1981. In the 137
cases of imported hepatitis reported, 78 were HAV infec-
tions. Case details were determined by reviewing hospital
charts and asking physicians who had requested the labora-
tory test to fill out a questionnaire (table 1) [6]. Investigators
estimated that ---50% of all HAV cases were missed (unpub-
lished data); some cases were diagnosed and treated abroad,
samples in all cases were not submitted for serotyping, and
sera were analyzed by laboratories outside the catchment
area. In addition, the study could not identify asymptomatic
infections. At a time when only hepatitis A and B could be
differentiated, more than half of all cases of hepatitis im-
ported from developing countries were clearly diagnosed as
hepatitis A. This infection accounted for "'60% of hepatitis
cases in travelers returning from Africa, Latin America, or
lID 1995; 171 (Suppl I)
Figure 1. Seroprevalence before
departure of anti-HAY in German
and Swiss travelers [3-5]. *History
of jaundice or stay in developing
country> I year.
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Table 1. Hepatitis A attack rate in Swiss travelers at various desti-
nations, 1977-1981 (n = 78).
south and Southeast Asia [6]. Trampers (e.g., hitchhikers
through India) had a much higher risk than other travelers.
Hepatitis B and non-A, non-B hepatitis were each diagnosed
in --15% of the cases, and almost 10%remained unclassified.
In contrast, hepatitis A played only a minor role in infections
acquired within Europe.
Obviously, various biases are inherent in such a retrospec-
tive study. Nevertheless, it appears that between various de-
veloping regions of the world, there was no marked differ-
ence in attack rates for hepatitis A (table I); in contrast, rates
were much lower in travelers to southern Europe. Although
the endemicity of hepatitis A in southern Europe has sub-
stantially decreased since World War II, rates are still higher
than in other industrialized areas.
How do findings from this study compare with those from
Destination
Northern Europe
North America
Southern Europe
North Africa
Subsaharan Africa
Near East
Middle East
Far East
Central America
South America
NOTE. From [6].
* Average.
Attack rate/ I000
journeys
0.2
o
1.5
62
125
45
181 80*
55
83
67
older studies that analyzed either all cases ofimported hepati-
tis or only imported non-B hepatitis? Table 2 shows similar
results from Swiss [6, 7] and Danish studies [8]; however, the
rates were markedly lower than both Swedish surveys [9, 10],
despite the fact that the latter did not include hepatitis B
cases. A partial explanation is that in comparison with other
populations, Swedish residents have the lowest prevalence of
anti-HAV antibody [2]. It is also possible that a larger pro-
portion of Swedish travelers went abroad to work and thus
stayed for a prolonged time. A British study showed mark-
edly lower attack rates; however, findings were qualified by
the fact that "only a fraction of those who contracted hepati-
tis A" were examined [I I].
In the only follow-up epidemiologic study of hepatitis in
travelers, 8 of almost 8000 visitors to developing countries
were diagnosed with symptomatic hepatitis A [12]. The ma-
jority were tourists who had stayed in hotels, often high-class
accommodations. The mean duration of incapacity to work
was r-- I month. Nine travelers had non-A, non-B hepatitis,
some of whom may have had pyrimethamine-sulfadoxine-
induced toxic hepatitis, and 2 professionals contracted hepa-
titis B while working in the tropics. Although the number of
patients is small, some observations were possible. The aver-
age duration of the stay abroad was 19 days. Thus, the esti-
mated case incidence rate per month (cases/persons/month)
was 1.6/ IODD/month. Since ---40% of travelers are anti-
HAY-positive by either infection or administration of im-
mune serum globulin (rSG) (unpublished data), the
corrected case rate for unprotected travelers is ---3/ I000/
month. Asymptomatic infections were disregarded in the pre-
ceding calculations [12].
French investigators studied hepatitis A seroconversion in
233 volunteers working in the bush ofcentral or West Africa
S26 Steffen
Table 2. Imported hepatitis (any serotype) attack rate per journey abroad.
Imported to
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Zurich [7] Copenhagen [8] Zurich [6] Goteborg [10] Stockholm [9]
Imported (n = 221) (n = 105) (n = 137) (n = 80) (n = 65)
from 1971-1976 1976-1978 1977-1981 1980 1982
Northern Europe 0.6 0.5 I NA NA
Southern Europe 10 3 4 20 5
North Africa 100 50 60 140 190
Other developing
countries 60-290 80 110 860 830
Trampers 2000 NA NA NA NA
NOTE. NA, not available.
from 1979 to 1980 [13]. In this group. 125 (54%) were anti-
HA V-positive before departure; the remaining 108 who
were anti-HAV-negative received no ISG during their stay.
The seroconversion rate was 19/ IODD/month, with most af-
fected patients developing jaundice.
Data from all available retrospective. follow-up, and sero-
conversion studies lead to the conclusion that symptomatic
hepatitis A develops in unprotected. nonimmune travelers
who journey from industrialized countries to developing re-
gions and stay for ~ I month. at a rate of 3/ IODD/month.
High rates also apply to short-term vacationers and business
persons staying in good. even four- or five-star. hotels.
Among trampers and other persons who eat and drink under
poor' hygienic conditions. the incidence rate increases six-
fold. Conversely. the rate is at least 50 times lower (i.e.•
0.05,-0.ljlOOO/month) in travelers who stay in southern Eu-
rope [7. 14]. Nobody thus far has assessed the incidence rate
of hepatitis A in nonimmune visitors to eastern Europe, but
considering that these are high-endemicity countries, the risk
at least in remote areas may be considered as high.
Impact of Hepatitis A on Travelers
Adults with hepatitis A are incapacitated for an average of
4-10 weeks. with the length of illness associated with age
[12]. A survey of airline crews showed that pilots (who are
usually older) were incapacitated for significantly longer pe-
riods than younger cabin crew members (Gutersohn T. per-
sonal communication). Children tolerate the infection better
and recover more rapidly; the case-fatality rate is very low
compared with that in adults. However. particularly nonim-
mune immigrant children visiting the home countries oftheir
parents are in close contact with native children and thus at
high risk of contracting HA V infection. Whether symptom-
atic or asymptomatic. they may spread the infection at home
or in day care centers [14]. For many years. the case-fatality
rate in adults has been underestimated; it may be >2% in
older persons [15. 16].
Impact of Imported Hepatitis A on the Community
Today, a large proportion ofcases ofhepatitis A in industri-
alized countries relates to the large number of travelers [17].
The proportion may differ from one year to the next because
of regional epidemics in drug addicts. This. in turn, leads to a
statistical decrease in the proportion ofcases in travelers. Lax
notification procedures may also contribute to variations. de-
pending on the level of awareness. An explanation of the
particularly high proportion of cases of imported hepatitis in
Switzerland is that 12%of the population visited a develop-
ing country in 1991 [18].
Morbidity and Mortality
Symptomatic hepatitis A clearly is the most frequently oc-
curring vaccine-preventable infection in travelers (figure 2).
In many areas of the world, the risk of HA V infection is
comparable to that of malaria among travelers who do not
use chemoprophylaxis. Although hepatitis B has lower inci-
dence rates. mortality estimates are of the same order ofmag-
nitude as in hepatitis A [15. 16, 19]. American and European
data. however. suggest that hepatitis B is rare in vacationers
[20]. The risk of hepatitis A in unprotected travelers to usual
destinations is 100 times higher than for typhoid fever and
1000 times higher than for cholera (reviewed in [21D. Like
hepatitis A. these two gastrointestinal infections have a low
case-fatality rate: ~2% in recent statistical evaluations.
Impact of Active Vaccine Use
In January 1992, an active vaccine against hepatitis A was
introduced in Switzerland and has been well received. Prelim-
inary data indicate an annual reduction by 15% in cases of
imported hepatitis A, and this trend is thought to be due to
active immunization of the majority of Swiss travelers [16].
Today. ISG is often refused. To date, no cases of serious side
effects or vaccine failure have been reported in -- 500.000
doses given to travelers in Switzerland.
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Conclusion
The European experience illustrates that hepatitis A is an
important health risk for travelers residing in industrialized
nations and visiting developing countries, particularly since
most are now susceptible to the infection. Travelers' hepati-
tis A has an important impact both on the individual. be-
cause of incapacitation lasting several weeks and a substan-
tial case-fatality rate in older adults, and on the community,
since a large proportion of these infections are imported.
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